Cell-based assays are analytical methods that are used to detect the potency and efficacy of drug candidates. These assays utilize living cells to study cellular activities and gain insights into complex disease pathologies for the discovery and development of new drug therapies. Cell-based assays offer several advantages over other in vitro methods such as high-throughput screening capabilities, ability to monitor cell toxicity, and assessment of drug actions at a cellular level. Growing R&D investments in pharmaceutical companies and expansion of stem cell research are major factors fueling demand for cell-based assays.
The global Cell-based Assay Market is estimated to be valued at US$ 1389.05 Mn in 2023 and is expected to exhibit a CAGR of 5.7% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market key trends:
The increased adoption of cell-based assays in drug discovery is one of the key trends driving market growth. Cell-based assays are gaining widespread acceptance owing to their comprehensive analysis of complex biological systems. They provide insights into disease mechanisms and pathology modeling which enables researchers to evaluate drug toxicity and efficacy at an early stage of development. This significantly reduces drug discovery costs and attrition rates. Furthermore, technological advancements in assay miniaturization, imaging solutions, and high-throughput screening platforms have improved data accuracy and enhanced screening outputs. These factors are expected to boost the demand for cell-based assays over the forecast period.
Segment Analysis
The global cell-based assay market can be segmented based on product, application, end user and region. By product, consumables accounted for the largest share in 2023 attributed to frequent usage of consumables like plates, reagents and kits. By application, drug discovery accounted for the major share owing to increasing R&D investments and adoption of cell-based assays for screening of drug candidates.
Key Takeaways
The global cell-based assay market is expected to witness high growth during the forecast period driven by advantages of cell-based assays over other techniques, technological advancements and rising R&D spending by pharmaceutical and biotechnology companies.
Regional analysis: North America accounted for the largest share of the global cell-based assay market in 2023 due to presence of major players, adoption of advanced technologies and availability of funding for research. Asia Pacific is expected to witness fastest growth during the forecast period owing to increasing outsourcing by pharmaceutical firms for drug discovery studies, rising healthcare expenditure and growing life sciences research.
Key players: Key players operating in the cell-based assay market are DiscoverX Corporation, Becton, Dickinson and Company, cell Signaling Technology, Inc., Becton, Danaher Corporation, Thermo Fisher Scientific, Inc., Cisbio Bioassays, Merck & Co., and PerkinElmer, Inc. and others. DiscoverX Corporation offers cell-based assays like kinase and GPCR assays using PathHunter technology to accelerate drug discovery process.
No comments:
Post a Comment